Results 61 to 70 of about 32,846 (250)

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

British Journal of Clinical Pharmacology, EarlyView.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath, Nicole S. L. Chan, Paul Joyce   +2 more
wiley   +1 more source

A study on the therapeutic effect of liraglutide on chronic renal failure rats by down-regulating TGF-β1 and α-SMA

Linchuang shenzangbing zazhi, 2020
Objective To explore the therapeutic effect of liraglutide on chronic renal failure(CRF)rats by down-regulating transforming growth factor-β1(TGF-β1)and α-smooth muscle actin(α-SMA).Methods Wistar rats were divided into sham group,chronic renal failure ...
CHEN Li, TANG Wen-zhuang, ZHU Mei-juan, CHEN Juan   +3 more
doaj  

Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis

Obesity Facts, 2017
Objective: To investigate whether the efficacy and safety of liraglutide 3.0 mg differed between two subgroups, BMI 27 to Methods: A post-hoc analysis of two 56-week, randomized, double-blind, placebo-controlled trials (SCALE Obesity and ...
Carel le Roux, Vanita Aroda, Joanna Hemmingsson, Ana Paula Cancino, Rune Christensen, Xavier Pi-Sunyer   +5 more
doaj   +1 more source

Liraglutide Promotes Osteoblastic Differentiation in MC3T3-E1 Cells by ERK5 Pathway

International Journal of Endocrinology, 2020
Liraglutide is a glucagon-like peptide-1 analogue widely used in the treatment of type 2 diabetes mellitus. However, the effects of liraglutide on osteoblast proliferation and differentiation in MC3T3-E1 cells have not been fully elucidated.
Yue Sun, Yuzhen Liang, Zhengming Li, Ning Xia   +3 more
doaj   +1 more source

A glucagon-like peptide-1 analog, liraglutide, ameliorates endothelial dysfunction through miRNAs to inhibit apoptosis in rats [PDF]

PeerJ, 2019
Background and Aims Many studies have revealed that glucagon-like peptide-1 has vasoprotective effects. In this study, we investigated whether liraglutide suppressed endothelial dysfunction and explored the mechanism involved.
Qian Zhang, Xinhua Xiao, Jia Zheng, Ming Li   +3 more
doaj   +2 more sources

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source

Association Between Exercise and Treatment with Liraglutide in Obese Rats by Cafeteria Diet [PDF]

Brazilian Archives of Biology and Technology, 2019
The objective of this study was to evaluate the effect of liraglutide, an analog of glucagon-like peptide-1 (GLP-1) in association with physical exercise, on the metabolic and biochemical parameters of rats induced to obesity with a cafeteria diet.
Daiane Didek, Maiara Mikuska Cordeiro, João Lucas de Paula Xavier, Paulo Roberto Ribeiro, Thiago Rentz, Gilson Cesar Nobre Franco, Carla Cristine Kanunfre, Henriette Rosa de Oliveira Emilio, Dionízia Xavier Scomparin   +8 more
doaj   +1 more source

Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus. [PDF]

, 2016
BACKGROUND: The pharmacokinetic properties of liraglutide, a glucagon-like peptide-1 receptor agonist approved for the treatment of type 2 diabetes mellitus (T2D), have been established in healthy individuals and subjects with T2D.
A Flint, A Garber, A Varanasi, AJ Garber, B Damholt, B Elbrønd, CS Frandsen, DJ Klein, Erik Christiansen, H Agersø, J Jiang, J Pettus, J Unger, JJ Neumiller, Julia K. Mader, K Hermansen, KB Degn, L Morrow, LB Harrison, LB Knudsen, Lene Jensen, LV Jacobsen, M Katout, ND Kuhadiya, S Irie, SH Ingwersen, SH Ingwersen, Simon Heller, Steen H. Ingwersen, TF Dejgaard, Thomas R. Pieber, TR Pieber, U Kielgast   +32 more
core   +2 more sources

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice [PDF]

, 2015
Type 2 diabetes is a risk factor for Alzheimer's disease (AD). Previously, we have shown that the diabetes drug liraglutide is protective in middle aged and in old APP/PS1 mice. Here, we show that liraglutide has prophylactic properties.
Holscher, Christian, Jalewa, Jaishree, McClean, Paula L.   +2 more
core   +1 more source